Leukemia Research
Volume 27, Issue 7 , Pages 593-598 , July 2003

Amifostine does not preferentially stimulate the growth of residual polyclonal progenitor cells in myelodysplastic syndromes

Received 5 March 2002 ,Accepted 4 June 2002.

References 

  1. Heaney ML, Golde DW. Myelodysplasia. N. Engl. J. Med. 1999;340:1649
  2. Rosenfeld C, List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia. 2000;14:2
  3. Boogaerts M, Verhoef G, Demuynck H. Treatment and prognostic factors in myelodysplastic syndromes. Baillieres Clin. Haematol. 1996;9:161
  4. De Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C, et al.  Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDS) and acute myeloid leukaemia following MDS. Blood. 2001;98:2326
  5. Delforge M, Demuynck H, Vandenberghe P, Verhoef G, Zachée P, Van Duppen V, et al.  Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood. 1995;86:3660
  6. Hellström-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, et al.  Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomised phase II study and long-term follow-up of 71 patients. Blood. 1998;92:68
  7. Seng JE, Peterson BA. Low dose chemotherapy for myelodysplastic syndromes. Leuk. Res. 1998;22:481
  8. Raza A, Qawi H, Lisak L, Andric T, Dar S, Andrews C, et al.  Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood. 2000;95:1580
  9. Jonásová A, Neuwirtová R, Cermák J, Vozobulová V, Mociková K, Sisková M, et al.  Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br. J. Haematol. 1998;100:304
  10. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profile. Br. J. Haematol. 1998;102:1314
  11. Silverman LR, Holland JF, Weinberg RS, Alter BP, Davis RB, Ellison RR, et al.  Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993;7(1):121
  12. Wijermans P, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M, et al.  Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol. 2000;18:956
  13. Lübbert M, Wijermans P, Kunzman R, Verhoef G, Bosly A, Ravoet C, et al.  Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br. J. Haematol. 2001;114:349
  14. Vadhan-Raj S, Broxmeyer H, Spitzer G, LeMaistre A, Hultman S, Ventura G, et al.  Stimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndrome. Blood. 1989;74:1491
  15. Janssen J, Buschle M, Layton M, Drexler H, Lyons J, Van den Berghe H, et al.  Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood. 1989;73:248
  16. Ganser A, Janssen J, Ottman O, Seipelt G, Eder M, Becher R, et al.  In vivo effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on clonal and non-clonal cell populations in patients with clonal hematopoietic disorders. Leukemia. 1991;5:487
  17. Balzarotti M, Grisanti S, Granzow K, Saladini A, Sala A, Nozza A, et al.  Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine. Semin. Oncol. 1999;26:66
  18. Mehta MP. Amifostine and combined-modality therapeutic approaches. Semin. Oncol. 1999;26:95
  19. List AF, Heaton B, Glinsmann-Gibson B, Capizzi RL. Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors. Leukemia. 1998;12:1596
  20. List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R, et al.  Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood. 1997;90:3364
  21. Ribizzi I, Darnowski JW, Goulette FA, Sertoli MR, Calabresi P. Amifostine cytotoxicity and induction of apoptosis in a human myelodysplastic cell line. Leuk. Res. 2000;24:519
  22. List AF. Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS?. Leuk. Res. 1998;22:S7
  23. Romano MF, Lamberti A, Bisogni R, Garbi C, Pagnano AM, Auletta P, et al.  Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-κB/Rel transcription factors. Blood. 1999;94(12):4060
  24. List AF. Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia. Semin. Oncol. 1999;26(7):61
  25. Bowen DT, Denzlinger C, Brugger W, Culligan D, Gelly K, Adlakha S, et al.  Poor response rate to a continuous schedule of Amifostine therapy for ‘low/intermediate risk’ myelodysplastic patients. Br. J. Haematol. 1998;103:785
  26. Delforge M, Demuynck H, Verhoef G, Vandenberghe P, Zachée P, Maertens J, et al.  Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission. Br. J. Haematol. 2000;102:486
  27. Anan K, Ito M, Misawa M, Ohe Y, Kohsaki M, Hara H. Clonal analysis of peripheral blood and haemopoietic colonies in patients with aplastic anaemia and refractory anaemia using the short tandem repeat on the human androgen-receptor (HUMARA) gene. Br. J. Haematol. 1995;89:838
  28. Aivado M, Rong A, Germing U, Gattermann N, Kobbe G, Rieth C, et al.  Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis. Br. J. Haematol. 2000;110:884
  29. Uchida T, Kinoshita T, Nagai H, Nakahara Y, Saito H, Hotta T, et al.  Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood. 1997;90:1403
  30. Meier T, Issels RD. Degradation of 2-(3-aminopropylamino)-ethanethiol (WR-1065) by Cu-dependent amine oxidases and influence on glutathione status of Chinese hamster ovary cells. Biochem. Pharmacol. 1995;50:489

PII: S0145-2126(02)00099-1

doi: 10.1016/S0145-2126(02)00099-1

Leukemia Research
Volume 27, Issue 7 , Pages 593-598 , July 2003

Article Tools

* Image Usage & Resolution